

RECEIVED 012
CENTRAL FAX CENTER

JUL 01 2004

In re: Nicolette
USSN: 09/922,405
Filed: August 3, 2001
Page 2

AMENDMENTS

OFFICIAL

Please amend the subject application as follows:

IN THE CLAIMS:

Please amend claims 1 and 2, and add new claim 10 as follows:

1. (currently amended) A composition comprising at least ~~[[two]]~~ one immunogenic ligands ligand, wherein said immunogenic ligands are ligand is individually characterized by an ability to elicit an immune response against the same native MART-1 ligand, and wherein said immunogenic ligand is selected from the group consisting of LSGIGILTV (SEQ ID NO:3), LTGIGILTV (SEQ ID NO:5), VTGIGILTV (SEQ ID NO:7), ~~FAGIGILTV (SEQ ID NO:9)~~ [[,]] TAGIGILTV (SEQ ID NO:11), GVGIGILTV (SEQ ID NO:13), FLFHYEYVV (SEQ ID NO:15), FLFHTAYIV (SEQ ID NO:17), FLYHTPMVV (SEQ ID NO:19), FLYHTPMIV (SEQ ID NO:21) [[,]] and FLTPLGPRV (SEQ ID NO:23) ~~and AAGIGILTV (SEQ ID NO:25)~~.
2. (currently amended) The composition of claim 1 or 10, further comprising a carrier.
3. (original) The composition of claim 2, wherein the carrier is a pharmaceutically acceptable carrier.
4. (original) A host cell comprising at least two immunogenic ligands, wherein said immunogenic ligands are individually characterized by an ability to elicit an immune response against the same native ligand, and wherein said immunogenic ligand is selected from the group consisting of LSGIGILTV (SEQ ID NO:3), LTGIGILTV (SEQ ID NO:5), VTGIGILTV (SEQ ID NO:7), FAGIGILTV (SEQ ID NO:9), TAGIGILTV (SEQ ID NO:11), GVGIGILTV (SEQ ID NO:13), FLFHYEYVV (SEQ ID NO:15), FLFHTAYIV (SEQ ID NO:17), FLYHTPMVV (SEQ ID NO:19), FLYHTPMIV (SEQ ID NO:21), FLTPLGPRV (SEQ ID NO:23) and AAGIGILTV (SEQ ID NO:25).
5. (original) The host cell of claim 4, wherein the host cell is an antigen presenting cell and the immunogenic ligands are presented on the surface of the cell.
6. (original) The host cell of claim 5, wherein the antigen presenting cell is a dendritic cell.
7. (original) A composition comprising the host cell of any of claims 4 to 6 and a carrier.
8. (original) The composition of claim 7, wherein the carrier is a pharmaceutically acceptable carrier.

In re: Nicolette
USSN: 09/922,405
Filed: August 3, 2001
Page 3

9. (original) A method for inducing an immune response in a subject, comprising delivering to the subject a composition comprising an effective amount of two or more immunogenic ligands, wherein each of said immunogenic ligands is characterized by an ability to elicit an immune response against the same native ligand, and wherein said immunogenic ligand is selected from the group consisting of LSGIGILTV (SEQ ID NO:3), LTGIGILTV (SEQ ID NO:5), VTGIGILTV (SEQ ID NO:7), FAGIGILTV (SEQ ID NO:9), TAGIGILTV (SEQ ID NO:11), GVGIGILTV (SEQ ID NO:13), FLFHYEYV (SEQ ID NO:15), FLFHTAYIV (SEQ ID NO:17), FLYHTPMVV (SEQ ID NO:19), FLYHTPMIV (SEQ ID NO:21), FLTPLGPRV (SEQ ID NO:23) and AAGIGILTV (SEQ ID NO:25).

10. (New) The composition of claim 1, further comprising the ligand FAGIGILTV (SEQ ID NO:9) or AAGIGILTV (SEQ ID NO:25).


REMARKS

Claims 1-9 are pending in the subject application and are subject to a restriction requirement mailed February 5, 2004, a full response to which is filed concurrently herewith. By this preliminary amendment, Applicant respectfully requests amendment of claims 1 and 2 and entry of new claim 10. Support for the amendment to the claims and the addition of new claim 10 is found in the application papers on page 4, lines 1 to 30; page 5, line 23 to page 6, line 19; page 26, line 7 to page 27, line 2 and lines 26 to 31; page 28, lines 13 to 23; and page 42, line 21 to page 44, line 2. An issue of new matter is not raised by the addition of these claims and entry thereof is respectfully requested.

CONCLUSION

No additional fee is deemed necessary in connection with the filing of this Preliminary Amendment. However, if the Patent Office determines that a fee and/or other relief is required, Applicant petitions for any required relief and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 07-1074.

Respectfully submitted,



Deborah A. Dugan
Attorney for Applicants
Registration No. 37,315
Telephone: (508) 270-2598
Facsimile: (508) 872-5415

GENZYME CORPORATION
15 Pleasant Street Connector
P.O. Box 9322
Framingham, Massachusetts 01701-9322